Progress in heart failure management in the Netherlands and beyond: long-term commitment to deliver high-quality research and patient care

Abstract

Heart failure (HF) remains a major global problem. In the Netherlands, 1.5-2.0% of the total population is diagnosed with HF. Over 30,000 HF patients are admitted annually in the Netherlands, and this number is expected to further increase given the ageing population and the chronic nature of HF. Despite ongoing efforts to reduce the burden of HF, morbidity and mortality rates of this disease remain high. However, several new treatment modalities have become available or are expected to become available in the coming years. This review will provide an overview of HF research conducted in the Netherlands (often in an international setting) that may have clinical consequences for diagnosis, treatment and prevention of HF, and will also evaluate outcomes of larger clinical trials that have been conducted in the Netherlands.

Keywords: Diuretics; Heart failure; Home monitoring; Nutrition; SGLT2 inhibitors; The Netherlands.

Fig. 1

Kaplan-Meijer curves of the effect of treatment with dapagliflozin on top of standardised HF care on: a Primary outcome; b Hospitalisation for heart failure (reproduced with permission) [24]

Fig. 2

a Overview of Dutch sites participating in MONITOR-HF; b The CardioMEMS sensor (with permission of Abbott Inc.); c The CardioMEMS HF system patient unit including antenna (with permission of Abbott Inc.); d Location of the CardioMEMS sensor in the left pulmonary artery (with permission of Abbott Inc)